| Autor: |
Soranno DE; Departments of Pediatrics, Bioengineering and Medicine, University of Colorado, Aurora, Colorado., Bihorac A; Department of Medicine and Precision and Intelligent Systems in Medicine (PrismaP), University of Florida, Gainesville, Florida., Goldstein SL; University of Cincinnati College of Medicine and Cincinnati Children's Hospital, Cincinnati, Ohio., Kashani KB; Division of Nephrology and Hypertension, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota., Menon S; University of Washington and Seattle Children's Hospital, Seattle, Washington., Nadkarni GN; Division of Data Driven and Digital Medicine (D3M) and Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York., Neyra JA; Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky Medical Center, Lexington, Kentucky., Pannu NI; University of Alberta, Edmonton, Alberta, Canada., Singh K; Department of Internal Medicine and School of Information, University of Michigan, Ann Arbor, Michigan., Cerda J; Department of Medicine, Albany Medical Center, Albany, New York., Koyner JL; Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois. |
| Abstrakt: |
Competing Interests: J. Cerda reports serving as chair of the ASN’s AKI!Now Initiative, as a scientific advisor for or member of the International Society of Nephrology (ISN) AKI Committee and cochair of the 0by25 Initiative, and as cochair of the ISN’s advisory committee; serving as associate director of the ASN AKI!Now Initiative and of the ISN’s 0by25 Initiative, and as a member of the ASN Online AKI Community; and having ownership interest in Capital District Renal Physicians (as shareholder). S. L. Goldstein reports having consultancy agreements with Akebia, Baxter Healthcare, Bayer, Bioporto Inc., CHF Solutions, Fresenius, Kaneka Inc., La Jolla Pharmaceuticals, MediBeacon, Medtronic, Otsuka, Reata, and Renibus; receiving research funding from Baxter Healthcare, Bioporto, and CHF Solutions; receiving honoraria from, and serving on speakers bureaus for, Baxter Healthcare and Fresenius; having ownership interest in, and serving as a scientific advisor for or member of, MediBeacon; and having patents and inventions with Vigilanz. K. B. Kashani reports having consultancy agreements with AM Pharma; serving as a scientific advisor for or member of Baxter, GE, La Jolla Inc., and MediBeacon Inc.; receiving research funding from La Jolla Inc.; having patents and inventions with MediBeacon; and receiving honoraria from Nikkiso. J. L. Koyner reports receiving honoraria from Acute Disease Quality Initiative (ADQI), ASN, and Society of Critical Care Medicine; serving as a scientific advisor for or member of the American Journal of Nephrology and Kidney360; being listed on a patent for Pi Glutathione-S-Transferase (GST) to detect severe AKI after cardiac surgery with Argutus Medical; having consultancy agreements with Astute Medical, Baxter, Novartis, and Mallinckrodt; receiving research funding from Astute Medical, Fresenius Medical, National Institutes of Health, and NxStage Medical; serving on the scientific advisory boards for the National Kidney Foundation (NKF) of Illinois and for the NKF; and serving on a speakers bureau for NxStage Medical. S. Menon reports having consultancy agreements with AKI Foundation and Nuwellis Inc. (CHF Solutions). G.N. Nadkarni reports receiving honoraria from AstraZeneca, BioVie, Lexicon, and Reata; having consultancy agreements with AstraZeneca, BioVie, Pensieve Health, Reata, Renalytix AI, Siemens, and Variant Bio; receiving research funding from Goldfinch Bio and Renalytix; having ownership interest in and serving as a scientific advisor for or member of, Pensieve Health and Renalytix; and having patents and inventions with Renalytix. J.A. Neyra reports serving as guest editor for Critical Care Nephrology in Advances in Chronic Kidney Disease, on the editorial board for Advances in Chronic Kidney Disease and Kidney360, and as a section editor for Clinical Nephrology; and having consultancy agreements with Baxter Healthcare Inc., Biomedical Insights, and Leadiant Biosciences. N.I. Pannu reports receiving honoraria from ADQI for the AKI meeting 2020 (US$1000.00 honorarium) and for the AKI CRRT meeting 2021 (provided microphone and lamp for speakers), ISN (as speaker, covered expenses 2019), and World Congress of Nephrology (as speaker, covered expenses in 2019 and 2020); having other interests in/relationships with Amgen (funded quality improvement initiative in ESKD); having consultancy agreements with GE; and serving as a scientific advisor for or membership of Kidney Foundation of Canada, Northern Alberta branch (on board of directors). K. Singh reports having other interests in/relationships with Blue Cross Blue Shield of Michigan (receive salary support through the University of Michigan for work done on the Michigan Urological Surgery Improvement Collaborative); receiving honoraria from Harvard University (for education provided in the Safety, Quality, Informatics, and Leadership program); and receiving research funding from Teva Pharmaceutical Ltd. D.E. Soranno reports having consultancy agreements with Levin & Perconti Attorneys at Law. The remaining author has nothing to disclose. |
